(Q38786414)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28503960%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

review article

1 reference

title

Management of severe complications in Behçet's disease with TNF inhibitors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28503960%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

0 references

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28503960%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

David Saadoun

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28503960%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

author name string

A C Desbois

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28503960%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

H Vallet

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28503960%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

F Domont

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28503960%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

C Comarmond

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28503960%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

language of work or name

English

0 references

publication date

19 May 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28503960%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Biological Therapy

20 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28503960%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28503960%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28503960%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

page(s)

853-859

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28503960%20AND%20SRC:MED&resulttype=core&format=json

Mortality in Behçet's disease.

20 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1328496

The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1328496

New insights into the pathogenesis of Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1328496

Critical role of IL-21 in modulating TH17 and regulatory T cells in Behçet disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1328496

Long-term outcome of arterial lesions in Behçet disease: a series of 101 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1328496

Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1328496

Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: Multicenter study of 124 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1328496

Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1328496

Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1328496

Adalimumab in Patients with Active Noninfectious Uveitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1328496

Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1328496

INTRAVITREAL INFLIXIMAB IN REFRACTORY UVEITIS IN BEHCET'S DISEASE: A Safety and Efficacy Clinical Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1328496

Efficacy and safety of adalimumab in Behçet's disease-related uveitis: a multicenter retrospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1328496

EULAR recommendations for the management of Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1328496

Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1328496

Pulmonary artery aneurysms in Behçet syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1328496

Pulmonary artery involvement and associated lung disease in Behçet disease: a series of 47 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1328496

An outcome survey of 43 patients with Budd-Chiari syndrome due to Behçet's syndrome followed up at a single, dedicated center

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1328496

Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1328496

Pulmonary artery aneurysms in Behçet's disease treated with anti-TNFα: A case series and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1328496

Behcet's disease with life-threatening haemoptoe and pulmonary aneurysms: complete remission after infliximab treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1328496

Pulmonary artery involvement in Behçet׳s syndrome: Effects of anti-Tnf treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1328496

Long-term outcome of neuro-Behçet's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1328496

Infliximab for the treatment of Neuro-Behçet's disease: a case series and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1328496

Infliximab is a plausible alternative for neurologic complications of Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1328496

Efficacy of Anti-TNFα in Severe and Refractory Neuro-Behcet Disease: An Observational Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1328496

Efficacy of infliximab in patients with intestinal Behçet's disease refractory to conventional medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1328496

Effects of anti-TNF-alpha antibody infliximab in refractory entero-Behcet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1328496

Efficacy of combination therapy of anti-TNF-α antibody infliximab and methotrexate in refractory entero-Behçet's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1328496

Long-Term Outcomes and Predictors of Sustained Response in Patients with Intestinal Behcet's Disease Treated with Infliximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1328496

Long-Term Efficacy of Adalimumab in Patients With Intestinal Behcet's Disease: Eight Consecutive Cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1328496

The 2nd edition of consensus statements for the diagnosis and management of intestinal Behçet's disease: indication of anti-TNFα monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1328496

Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1328496

Cancer risk of anti-TNF-α at recommended doses in adult rheumatoid arthritis: a meta-analysis with intention to treat and per protocol analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1328496

Factors affecting the tuberculosis risk in patients receiving anti-tumor necrosis factor-α treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1328496

Diagnosis and management of Neuro-Behçet's disease: international consensus recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1328496

Inhibition of interleukin-1 by canakinumab as a successful mono-drug strategy for the treatment of refractory Behçet's disease: a case series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1328496

Biological treatments in Behçet's disease: beyond anti-TNF therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1328496

Tocilizumab for severe refractory neuro-Behçet: three cases IL-6 blockade in neuro-Behçet.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1328496

Apremilast for Behçet’s Syndrome — A Phase 2, Placebo-Controlled Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1328496

Anti-TNF- therapy in patients with refractory uveitis due to Behcet's disease: a 1-year follow-up study of 124 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1328496

Infliximab Versus Adalimumab in the Treatment of Refractory Inflammatory Uveitis: A Multicenter Study From the French Uveitis Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1328496

Association study of IL10 and IL23R-IL12RB2 in Iranian patients with Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1328496

10.1080/14712598.2017.1328496

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28503960%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

1 reference